Page 1

Theravance Biopharma Medicines That Make a Difference Theravance Biopharma , Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update August 3 , 2021 - · Company reiterates Q3 2021 top - line results timing for ampreloxetine Phase 3 and izencitinib Phase 2b in ulcerative colitis - Company's implied 35 % share of YUPELRIⓇ ( revefenacin ) US net sales ( 1 ) : $ 14.6 million , up 38 % from Q2 2020 - TRELEGY® Q2 2021 global net sales hit $ 405 million , up 68 % from Q2 2020 ( 2 ) DUBLIN , Aug. 3 , 2021 / PRNewswire / -- Theravance Biopharma , Inc. ( " Theravance Biopharma " or the " Company " ) ( NASDAQ : TBPH ) today reported financial results for the second quarter of 2021 . " We made strong progress in the second quarter . Our field team is energized and has recently been able to increase its face - to - face engagements with customers , driving continued sales volume and market share growth . As we look to the future for YUPELRI , we and our partner Viatris are initiating a controlled clinical study intended to provide data for a possible label update , " said Rick E Winningham , Chief Executive Officer . " We continued to execute across our clinical trials and eagerly anticipate study results this quarter and later this year / early next . 2021 is a pivotal year for Theravance Biopharma , and we are looking forward to the second half of the year furthering our mission of medicines that make a difference . " Upcoming Clinical Milestones • Q3 2021 : Izencitinib ( gut - selective oral pan - Janus kinase ( JAK ) inhibitor for inflammatory intestinal diseases ) Phase 2b in ulcerative colitis ( study 0157 ) – top - line results expected in Q3 2021 . • Q3 2021 : Ampreloxetine ( norepinephrine reuptake inhibitor ) Phase 3 for symptomatic neurogenic orthostatic hypotension ( study 0169 ) - enrollment complete and top - line results expected in Q3 2021 . • Q4 2021 / Q1 2022 : Izencitinib ( gut - selective oral pan - JAK inhibitor for inflammatory intestinal diseases ) Phase 2 in Crohn's disease ( study 0173 ) - top - line results expected in late Q4 2021 / early Q1 2022 . Quarterly Highlights • YUPELRIⓇ ( revefenacin ) inhalation solution , the first and only once - daily , nebulized bronchodilator approved in the U.S. for the maintenance treatment of patients with chronic obstructive pulmonary disease ( COPD ) , continued to increase its share of the long - acting nebulized COPD market , increasing to 21 % in April 2021 , up from 19 % in January 2021 , and net sales increased by 38 % year - over - year ( Q2 2020 vs. Q2 2021 ) . • The Company , in collaboration with our partner Viatris , is also initiating a Phase 4 study comparing improvements in lung function in adults with severe to very severe COPD and suboptimal inspiratory flow rate following once - daily treatment with either YUPELRI® ( revefenacin ) delivered via standard jet nebulizer or tiotropium delivered via a dry powder inhaler ( SpirivaⓇ HandiHalerⓇ ) . This study is aimed at helping to better inform decisions when physicians are designing a personalized COPD treatment plan with patients . • Nezulcitinib , an investigational , inhaled , lung - selective , pan - JAK inhibitor in development for hospitalized patients with COVID - 19 , reported Phase 2 top - line results ( read more about the data here ) . • On June 29 , 2021 , the Company closed a public offering of ordinary shares at a price to the public of $ 15.00 per share , with gross proceeds of $ 115.6 million , before deducting underwriting discounts and commissions and offering expenses . Economic Interest • TRELEGY ( first once - daily single inhaler triple therapy for COPD and asthma ) , in which the Company holds an economic interest , posted second quarter 2021 global net sales of $ 405 million ( up from $ 241 million , 68 % , in the second quarter of 2020 ) ; Theravance Biopharma is entitled to tiered payments equal to approximately 5.5 % to 8.5 % of TRELEGY global net sales.3 Second Quarter Financial Results • Revenue : Total revenue for the second quarter of 2021 was $ 12.9 million , comprised of non - cash collaboration revenue of $ 2.0 million primarily attributed to our global collaboration with Janssen and $ 10.9 million in Viatris collaboration revenue . Total revenue for the second quarter represents a $ 2.1 million decrease over the same period in 2020 .